Patient-Tailored, Imaging-Guided, Long-Term Temozolomide Chemotherapy in Patients with Glioblastoma
We present two patients with glioblastoma with an unusually stable clinical course and long-term survival who were treated after surgery and radiotherapy with adjuvant temozolomide (TMZ) chemotherapy for 17 and 20 cycles, respectively. Afterward, adjuvant TMZ chemotherapy was discontinued in one pat...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2010-01-01
|
| Series: | Molecular Imaging |
| Online Access: | https://doi.org/10.2310/7290.2010.00002 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841564531935936512 |
|---|---|
| author | Norbert Galldiks Lutz W. Kracht Lothar Burghaus Roland T. Ullrich Heiko Backes Anna Brunn Wolf-Dieter Heiss Andreas H. Jacobs |
| author_facet | Norbert Galldiks Lutz W. Kracht Lothar Burghaus Roland T. Ullrich Heiko Backes Anna Brunn Wolf-Dieter Heiss Andreas H. Jacobs |
| author_sort | Norbert Galldiks |
| collection | DOAJ |
| description | We present two patients with glioblastoma with an unusually stable clinical course and long-term survival who were treated after surgery and radiotherapy with adjuvant temozolomide (TMZ) chemotherapy for 17 and 20 cycles, respectively. Afterward, adjuvant TMZ chemotherapy was discontinued in one patient and the dosage of TMZ was reduced in the other. In addition to clinical status and magnetic resonance imaging, the biologic activity of the tumors was monitored by repeated methyl- 11 C-l-methionine (MET) and 3′-deoxy-3′- 18 F-fluorothymidine (FLT) positron emission tomography (PET) studies in these patients. In these patients, repeated MET-and FLT-PET imaging documented complete response to the initial treatment regimen, including resection, radiation, and TMZ, and during the course of the disease, recurrent, uncontrollable tumor activity. Continuation or dose escalation of TMZ in both patients was shown to be ineffective to overcome the metabolic activity of the tumor. Our data suggest that repeated MET- and FLT-PET imaging provide information on the biologic activity of a tumor that is highly useful to monitor and detect changes in activity. |
| format | Article |
| id | doaj-art-4b58576c4a7b47c38e7a94c21189800b |
| institution | Kabale University |
| issn | 1536-0121 |
| language | English |
| publishDate | 2010-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Molecular Imaging |
| spelling | doaj-art-4b58576c4a7b47c38e7a94c21189800b2025-01-02T22:37:34ZengSAGE PublishingMolecular Imaging1536-01212010-01-01910.2310/7290.2010.0000210.2310_7290.2010.00002Patient-Tailored, Imaging-Guided, Long-Term Temozolomide Chemotherapy in Patients with GlioblastomaNorbert GalldiksLutz W. KrachtLothar BurghausRoland T. UllrichHeiko BackesAnna BrunnWolf-Dieter HeissAndreas H. JacobsWe present two patients with glioblastoma with an unusually stable clinical course and long-term survival who were treated after surgery and radiotherapy with adjuvant temozolomide (TMZ) chemotherapy for 17 and 20 cycles, respectively. Afterward, adjuvant TMZ chemotherapy was discontinued in one patient and the dosage of TMZ was reduced in the other. In addition to clinical status and magnetic resonance imaging, the biologic activity of the tumors was monitored by repeated methyl- 11 C-l-methionine (MET) and 3′-deoxy-3′- 18 F-fluorothymidine (FLT) positron emission tomography (PET) studies in these patients. In these patients, repeated MET-and FLT-PET imaging documented complete response to the initial treatment regimen, including resection, radiation, and TMZ, and during the course of the disease, recurrent, uncontrollable tumor activity. Continuation or dose escalation of TMZ in both patients was shown to be ineffective to overcome the metabolic activity of the tumor. Our data suggest that repeated MET- and FLT-PET imaging provide information on the biologic activity of a tumor that is highly useful to monitor and detect changes in activity.https://doi.org/10.2310/7290.2010.00002 |
| spellingShingle | Norbert Galldiks Lutz W. Kracht Lothar Burghaus Roland T. Ullrich Heiko Backes Anna Brunn Wolf-Dieter Heiss Andreas H. Jacobs Patient-Tailored, Imaging-Guided, Long-Term Temozolomide Chemotherapy in Patients with Glioblastoma Molecular Imaging |
| title | Patient-Tailored, Imaging-Guided, Long-Term Temozolomide Chemotherapy in Patients with Glioblastoma |
| title_full | Patient-Tailored, Imaging-Guided, Long-Term Temozolomide Chemotherapy in Patients with Glioblastoma |
| title_fullStr | Patient-Tailored, Imaging-Guided, Long-Term Temozolomide Chemotherapy in Patients with Glioblastoma |
| title_full_unstemmed | Patient-Tailored, Imaging-Guided, Long-Term Temozolomide Chemotherapy in Patients with Glioblastoma |
| title_short | Patient-Tailored, Imaging-Guided, Long-Term Temozolomide Chemotherapy in Patients with Glioblastoma |
| title_sort | patient tailored imaging guided long term temozolomide chemotherapy in patients with glioblastoma |
| url | https://doi.org/10.2310/7290.2010.00002 |
| work_keys_str_mv | AT norbertgalldiks patienttailoredimagingguidedlongtermtemozolomidechemotherapyinpatientswithglioblastoma AT lutzwkracht patienttailoredimagingguidedlongtermtemozolomidechemotherapyinpatientswithglioblastoma AT lotharburghaus patienttailoredimagingguidedlongtermtemozolomidechemotherapyinpatientswithglioblastoma AT rolandtullrich patienttailoredimagingguidedlongtermtemozolomidechemotherapyinpatientswithglioblastoma AT heikobackes patienttailoredimagingguidedlongtermtemozolomidechemotherapyinpatientswithglioblastoma AT annabrunn patienttailoredimagingguidedlongtermtemozolomidechemotherapyinpatientswithglioblastoma AT wolfdieterheiss patienttailoredimagingguidedlongtermtemozolomidechemotherapyinpatientswithglioblastoma AT andreashjacobs patienttailoredimagingguidedlongtermtemozolomidechemotherapyinpatientswithglioblastoma |